Inflammatory Bowel Disease Management During the COVID-19 Outbreak : The Ten Do's and Don'ts from the ECCO-COVID Taskforce
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com..
Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and on appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as inflammatory bowel disease [IBD]. In this review, we have compiled existing evidence on the impact of COVID-19 in IBD patients and provide guidance on the most appropriate care to adopt during the pandemic. Our review highlights that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management should be carefully adapted: [i] in SARS-CoV-2-positive IBD patients, medical treatments should be re-evaluated [with a particular focus on corticosteroids] always with the purpose of treating active disease and maintaining remission; [ii] non-urgent surgeries and endoscopic procedures should be postponed for all patients; [iii] online consultancy should be implemented; and [iv] hospitalization and surgery should be limited to life-threatening situations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 14(2020), 14 Suppl 3 vom: 21. Okt., Seite S798-S806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magro, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 25.06.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjaa160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312984979 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312984979 | ||
| 003 | DE-627 | ||
| 005 | 20231225145609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjaa160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM312984979 | ||
| 035 | |a (NLM)32722754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magro, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammatory Bowel Disease Management During the COVID-19 Outbreak |b The Ten Do's and Don'ts from the ECCO-COVID Taskforce |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 25.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and on appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as inflammatory bowel disease [IBD]. In this review, we have compiled existing evidence on the impact of COVID-19 in IBD patients and provide guidance on the most appropriate care to adopt during the pandemic. Our review highlights that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management should be carefully adapted: [i] in SARS-CoV-2-positive IBD patients, medical treatments should be re-evaluated [with a particular focus on corticosteroids] always with the purpose of treating active disease and maintaining remission; [ii] non-urgent surgeries and endoscopic procedures should be postponed for all patients; [iii] online consultancy should be implemented; and [iv] hospitalization and surgery should be limited to life-threatening situations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a covid management | |
| 650 | 4 | |a inflammatory bowel disease | |
| 700 | 1 | |a Rahier, J-F |e verfasserin |4 aut | |
| 700 | 1 | |a Abreu, C |e verfasserin |4 aut | |
| 700 | 1 | |a MacMahon, E |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, A |e verfasserin |4 aut | |
| 700 | 1 | |a van der Woude, C J |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, H |e verfasserin |4 aut | |
| 700 | 1 | |a Adamina, M |e verfasserin |4 aut | |
| 700 | 1 | |a Viget, N |e verfasserin |4 aut | |
| 700 | 1 | |a Vavricka, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kucharzik, T |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, S |e verfasserin |4 aut | |
| 700 | 1 | |a Siegmund, B |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, S |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 14(2020), 14 Suppl 3 vom: 21. Okt., Seite S798-S806 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:14 Suppl 3 |g day:21 |g month:10 |g pages:S798-S806 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjaa160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 14 Suppl 3 |b 21 |c 10 |h S798-S806 | ||